Abstract
INTRODUCTION
Colorectal cancer (CRC) is the most prevalent gastroin testinal tract malignancy worldwide among both men and women. Overall CRC incidence and mortality rates have been declining over the recent decades, yet CRC ranks third overall among other malignancies in men and women [1] . In China, there were approximately 376300 new cases and 191000 potential deaths for CRC in 2015 [2] . Despite several therapeutic advancements including surgical resection, neoadjuvant chemoradi otherapy, and targeted therapy, the prognosis of CRC patients remains relatively poor. With unprecedented survival benefits in selected patients, immunotherapy has become a promising treatment strategy and continuous progress has been made with immunomodulatory agents that target immune system checkpoints such as anti programmed death 1 (PD1) and cytotoxic Tlymphocyte antigen 4 (CTLA4) [3] . B7 homolog 3 (B7H3), also known as CD276, is a type I transmembrane glycoprotein that belongs to the B7/CD28 immunoglobulin superfamily. B7H3 mRNA is widely expressed on many tissues and cell types. However, B7H3 protein is not constitutively expressed on Tcells, natural killer cells and antigenpresenting cells, and its expression can be induced on immune cells. While limited expression has been noticed on normal tissues, overexpression is observed in a majority of human malignancies including CRC [4] and has been correlated with the poor prognosis of patients [5] . Moreover, B7H3 has been suggested to promote tumor growth, migration, invasion, and metastasis. Thus, it may be a potential therapeutic target for active immunotherapy.
The β1,3galactosyltransferase4 (B3GALT4) gene belongs to the β1,3galactosyltransferase (β3GalT) gene family, which encodes type II membranebound glycoproteins and is located in the centromeric segment of the human MHC class II region [6] . This gene is abundantly expressed in human organs and tissues, predominantly in the brain and involved in GM1/GD1 ganglioside synthesis [7] . The β3GalT family plays an essential role in the Oglycosylation process. The surface of cancer cells express glycoproteins, which are rich in Oglycosylation domains [8] . Thus, the family may be closely related to the tumor. Besides, Seko et al [9] had confirmed that B3GALT4 could be used as a novel biomarker for the diagnosis of gynecological cancers. However, there are insufficient reports about the correlation between B3GALT4 and CRC.
Therefore, the present study aimed to investigate the clinical correlation of B7H3 and B3GALT4 with CRC. Further, correlation between the expression of B7H3 and B3GALT4 was evaluated to determine their prognostic significance in CRC.
MATERIALS AND METHODS

Patients and tissue samples
The medical records of patients who received a histopathological diagnosis and underwent surgery for CRC at Affiliated Hospital of Jiangnan University between June 2008 and December 2011 were retrieved. A total of 223 formalinfixed paraffinembedded CRC tissue samples were included in the study. These patients did not receive radiotherapy or chemotherapy before the surgery. Only histologically confirmed cases were included in the study. However, patients who received chemo or radiotherapy before surgery and cases with incomplete clinical data were excluded from the study. The study was approved by the Medical Ethics Committee of Affiliated Hospital of Jiangnan University, and written informed consent was obtained from all patients. All the patients were followed up by telephone up to October 31, 2017, to obtain the survival data. The median follow up was 79 mo (range, 6114 mo).
Tissue microarray preparation
Two experienced pathologists examined the section stained with hematoxylin and eosin and marked the carcinoma sites in the corresponding paraffin block. Using a manual tissue microarrayer (Quick-Ray, UNITMA, Seoul, Korea), tissue cylinders with a 1.0 mm diameter were punched from representative tissue areas of each donor tissue block and implanted into the hole of the premade recipient paraffin block (UNITMA, Seoul, Korea). The tissue microarray paraffin block was then constructed and cut into 4 μm thick continuous sections, which were attached to antidewaxing slides and stored at room temperature.
Immunochemistry
The tissue paraffin blocks were serially sectioned into a 4 μm thickness, dewaxed in xylene, and hydrated in an ethanol gradient. Antigen retrieval was performed by heating the tissue sections at 100 ℃ for 30 min in citrate buffer. Moreover, endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 10 min. Subsequently, the sections were incubated in 5% bovine serum albumin at room temperature for 30 min. Primary antibodies, mouse antihuman B7H3 monoclonal antibody (1:200, Santa Cruz, Dallas, TX, United States) and rabbit antihuman B3GALT4 monoclonal antibody (1:50, Abcam, Cambridge, MA, United States) respectively were added dropwise followed by overnight incubation at 4 ℃. The slides were washed and incubated with a horseradish peroxidaseconjugated secondary antibody for 30 min. The immunostaining was carried out by staining with 3,3'diaminobenzidine tetrahydrochloride solution (GTVisionII Immunohistochemistry Detection Kit for Rabbit/Mouse, Gene Tech, Shanghai, China), counter stained with hematoxylin, dehydrated, and mounted. Sections were examined under a microscope.
Evaluation of immunochemistry staining
Two independent pathologists performed a blinded manner review of the sections. Both the intensity and extent of immunological staining were analyzed semi quantitatively. According to the percentage of positively stained cells, the sections were graded by five levels: 0 (≤ 5%), 1 (6%-25%), 2 (26%-50%), 3 (51%-75%) and 4 (> 76%). The staining intensity was scored similarly, with 0 used for negative staining, 1 for weakly positive, 2 for moderately positive and 3 for strongly positive. The scores for the percentage of positive cells and the staining intensity were multiplied to generate an immunereactive score for each specimen (012). Based on the total score, scores of 03 were considered as the low expression group, and scores of 412 were defined as the high expression group.
Cell lines and culture
The two human CRC cell lines, SW480 and Caco2, which exhibited different expression levels of B7H3 were maintained in our lab. We constructed SW480 cells that expressed a high level of B7H3 (SW480B7H3) by transfection with an overexpression plasmid, and Caco2 cells were stably transfected with a B7H3 shRNA (Caco2shB7H3). Cells transfected with a mock vector were used as negative controls (SW480NC and Caco 2shNC). SW480NC and SW480B7H3 were cultured in L15 medium (HyClone GE Healthcare Life Sciences, South Logan, UT, United States). Caco-2-NC and Caco2shB7H3 were maintained in RPMI1640 medium (the same as above). All the media were supplemented with 10% fetal bovine serum (Clark Bioscience, Houston, TX, United States). The cells were incubated at 37 ℃ in a humidified atmosphere with 5% CO2.
RNA extraction and cDNA synthesis
Total RNA was extracted from 1 × 10 6 cells using TRIzol (Invitrogen, Carlsbad, CA, United States), according to the manufacturer's protocol. A NanoDrop 2000 Spectrophotometer (Thermo Scientific, Waltham, MA, United States) was used to estimate the purity and concentration of total RNA by measuring the optical density. The first strand cDNA was generated from 1 μg RNA using the HiScript II 1st Strand cDNA Synthesis Kit (Vazyme, Nanjing, China) following the manufacturer's instructions.
Real-time quantitative polymerase chain reaction
The expression levels of B7H3 and B3GALT4 were detected using the QuantiNova TM SYBR Green PCR
Time PCR System (Applied Biosystems, Foster City, CA, United States). βactin was used as an internal control for normalization of the expression data. The first strand cDNA was amplified in a total 20 μL PCR reaction mixture: 10 μL 2 x QuantiNova SYBR Green PCR Master Mix, 0.1 μL QN ROX Reference Dye, 0.4 μL of each specific primer set, 2 μL cDNA and ddH2O added to 20 μL. The sequences of primers were as follows: βactin 5'CATGTACGTTGCTATCCAGGC3' (sense), 5'CTCCTTAATGTCACGCACGAT3' (antisense); B7H3 5'AGCACTGTGGTTCTGCCTCACA3' (sense), 5'CACCAGCTGTTTGGTATCTGTCAG3' (antisense); B3GALT4 5'ACTCCTACCGCAACCTCA3' (sense), 5' CACATCATCGTCCGTCTT3' (antisense). Each sample and internal control gene were run in triplicate, using an amplification condition of denaturation at 95 ℃ for using immunochemistry in CRC tissue. Positive staining of B7H3 was predominantly detected in the membrane and cytoplasm ( Figure 1C ), and the location of B3GALT4 expression was identified in the cytoplasm ( Figure  1D ). The positive rates of the B7H3 and B3GALT4 expressions were 70.4% (157/223) and 54.7% (122/223), respectively. Further, a highly significant correlation between the positive expression of B7H3 with the depth of tumor invasion (P = 0.049), distant metastasis (P = 0.034) and differentiation (P = 0.017) was observed. However, the expression of B3GALT4 had no significant correlation with clinicopathological parameters (Table 1) .
Correlation between B7-H3 and B3GALT4 expression in CRC
Of the 223 CRC cases, 97 (43.5%) patients exhibited higher expression of both B7H3 and B3GALT4, and 41 (18.4%) showed lower expression of both. Also, there were 85 (38.1%) cases with either B7H3 low or B3GALT4 low. Spearmen's Correlation was used to examine the association of B7H3 expression with B3GALT4 expression in CRC. The result showed that there was a highly significant positive correlation between B7H3 and B3GALT4 expression (r = 0.219, P = 0.001, Table 2 ).
High expression of B7-H3 and B3GALT4 in patients with CRC is associated with poor OS
Notably, patients with high expression of B7H3 had a significantly worse OS as compared to patients with low expression (P = 0.037) (Figure 2A) . Similarly, the OS in the high B3GALT4 expression group was significantly inferior to that in the low expression group (P = 0.044) ( Figure 2B ). Moreover, a subgroup of patients with high expression of B7H3 and high B3GALT4 exhibited a significantly worse prognosis as compared to patients with a low expression of B3GALT4 (P = 0.016) ( Figure 2C ). However, in a subgroup of patients with low expression of both B7H3 and B3GALT4 prognosis of patients with CRC was unaffected (P = 0.061) ( Figure 2D ). Furthermore, the univariate Cox proportional hazard model analysis was performed to evaluate the risk factors related to the prognosis of patients with CRC. As shown in Table 3 , high expression of B7H3, high expression of B3GALT4, high expression of both B7H3 and B3GALT4, depth of tumor invasion (T3/4), lymph node metastasis (N1/2), distant metastasis, TNM stage (III/IV), neural invasion, and vascular invasion were correlated with the OS of patients with CRC. However, there was no correlation of OS with gender, age, tumor location, colon cancer site, mucinous adenocarcinoma, differentiation, and B7H3 low expression group (Table  3) . Besides, the multivariate analysis revealed that distant metastasis, TNM stage (III/IV), and vascular invasion were significant independent prognostic factors for OS of patients with CRC (Table 3) . 
Western blotting
Total proteins were extracted from 1 × 10 6 cells by using icecold RIPA lysis buffer containing a cocktail of protease inhibitors (KeyGEN BioTECH, China) for 30 min. The concentrations of whole cell proteins were determined using a BCA Protein Assay Kit (CWBio, Beijing, China) and adjusted to the same concentration. For western blotting assay, the proteins of equal quantity were separated by 10% SDSPAGE and then transferred onto a PVDF membrane (Merck Millipore, Germany). After blocking with 5% nonfat dry milk for 1 h at room temperature, the membranes were incubated with the primary antibodies at a concentration of 1:1000 at 4 ℃ overnight. 
Statistical analysis
Statistical analysis of clinical data was performed using the software package SPSS 19.0 software (IBM, Chicago, IL, United States). Chi-square test analyzed the association between B7H3 or B3GALT4 and the clinicopathological data. The nonparametric Spearman test evaluated the correlation of B7H3 and B3GALT4 expression. Overall survival (OS) was plotted using the KaplanMeier method and was compared using the log rank test. Multivariate survival analysis was performed using the Cox proportional hazard model. All the in vitro experiments were performed in triplicate. A nonpaired ttest analyzed differences in mean values between groups. All data were analyzed using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, United States). A P-value less than 0.05 indicated a statistically significant difference.
RESULTS
Expression of B7-H3 and B3GALT4 and their relationship with clinicopathological features of CRC
The expression of B7H3 and B3GALT4 was analyzed
Correlation between B7-H3 and B3GALT4 in CRC cell lines
We further investigated the relationship between expression of B7H3 and B3GALT4 in vitro. The mRNA and protein expression was detected in the CRC cell lines with different B7H3 expression levels, which were maintained in our lab. Both the mRNA and protein expression of B7H3 and B3GALT4 were significantly upregulated in SW480B7H3 cell line expressing a high level of B7H3 as compared to SW480NC cell line. Similarly, as compared to Caco2shNC cell line, Caco2shB7H3 cell line with low expression of B7H3 significantly downregulated the expression of B3GALT4. Therefore, B7H3 and B3GALT4 had a positive correlation both in mRNA and protein expression in vitro (Figure 3 ).
DISCUSSION
CRC continues to be a major cause of cancerrelated morbidity and mortality with over 1200000 cases diagnosed every year, and more than 600000 patients succumb to the disease worldwide. Moreover, five year survival rates for stage I CRC was more than 90%
where as for stage IV was 10% [10] . Given the poor prognosis of CRC, the search for novel diagnostic and prognostic biomarkers is highly desirable to prevent CRCrelated deaths.
Immune checkpoint signaling pathways are most frequently modulated in cancer to inhibit the nascent antitumor immune response. Checkpoint antibody inhibitors, such as CTLA4 and PD1/PDL1 are the most extensively studied novel class of inhibitors. Currently, drugs inhibiting these pathways are employed for a wide variety of malignancies and have demonstrated durable antitumor activities in a subset of cancer patients [11, 12] . Furthermore, investigations on new inhibitory pathways are also undergoing, and drugs are being investigated including those targeting B7H3 [13] . As an immune checkpoint protein, B7H3 has been recognized as an immunoregulatory molecule for T cell activation, proliferation, and cytokine production [14] . Thus far, overexpression of B7H3 has been reported in several different cancer types and the expression level of B7H3 correlated with tumor growth, invasion, metastasis, malignant stage, and recurrence rate [15] . Furthermore, several groups have generated antiB7H3 antibodies and reported overall suppression of tumor growth in vitro and in vivo [16] . Therefore, it is expected that B7H3 plays a crucial role in cancer diagnosis and treatment. The present study revealed that B7H3 was highly expressed in CRC tissue (70.4%) and significantly associated with the depth of tumor invasion (P = 0.049), distant metastasis (P = 0.034) and differentiation (P = 0.017). These results were consistent with previous findings [17, 18] . Furthermore, B7H3 is a type I transmembrane glycoprotein and plays a role in immunosuppression. Chen et al [19] demonstrated that glycoprotein B7H3
was involved in the pathological process and tumor growth of oral squamous cell carcinoma, and the glycans of B7H3 from oral cancer cells comprised of terminal α-galactoses and more diverse N-glycan structures with higher fucosylation than that of healthy cells. In addition, the presence of a carbohydratelectin receptor interaction between the tumorassociated B7H3 from oral cancer cells and immune cells was detected [19] . B3GALT4, encoding a UDP-galactose: βNacetylgalactosamine β1,3galactosyltransferase activity, belongs to the human β3galactosyltransferase gene family [7] .
Galactosyltransferase (GT) of the glycosyltransferase family, is the most common Golgi "marker" enzyme, catalyzes the transfer of galactose to glycoprotein bound acetylglucosamine. The enzyme is provided with one Nlinked oligosaccharide and palmitate residues and plays a vital role in the process of Oglycosylation. Moreover, in patients suffering from ovarian and breast cancer, increased expression of GT enzyme activity has been reported [20] . Enzymatic activity of B3GALT4 and T5 in ovarian cancer tissues, and significant overexpression of B3GALT4/T5 mainly in stage I uterine corpus cancers, indicated that B3GALT4/T5 is a novel tumor marker for uterine corpus cancer and other gynecological cancers [9] . Consequently, B7H3 and B3GALT4 were both correlated with glycosylation and tumor progession. However, there was a paucity of literature on the expression and association of B7H3 and B3GALT4 in CRC. Therefore, the association of B7H3 and B3GALT4 expression in CRC tissues and cell lines was investigated.
The present study revealed that high expression of B7H3 or B3GALT4 reduced the OS rate of CRC patients independently (P = 0.037, P = 0.044, respectively). Furthermore, overexpression of both B7H3 and B3GALT4 in CRC resulted in poorer prognosis (P = 0.016). Besides, there was a significant positive correlation between B7H3 and B3GALT4 (r = 0.219, P = 0.001). Taken together, B7H3 and B3GALT4 could serve as a novel, reliable prognostic marker for CRC. Furthermore, we detected that the expression of B3GALT4 was positively altered following B7H3 expression in vitro. Combined with the results of clinical samples, this study indicated that B7H3 could positively regulate B3GALT4 at the mRNA as well as the protein level. However, the underlying mechanism of regulation of B7H3 and B3GALT4 in CRC warrants further investigation. In summary, the present study for the first time revealed the expression of B3GALT4 in CRC and its correlation with B7H3 in vitro. Overall, the findings of the present study suggested that B7H3 and B3GALT4 are novel prognostic biomarkers for CRC and highlight the significance of both B7H3 and B3GALT4 as promising therapeutic targets for CRC. Thus, here we present our preliminary work on the relationship of the immune function and glycosylation of tumorassociated protein in CRC.
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Research motivation
There are insufficient reports about the correlation between B3GALT4 and CRC.
Research objectives
The aim of the present study is to investigate the clinical correlation of B7-H3 and B3GALT4 with CRC, and the correlation between the expression of B7-H3 and B3GALT4 was evaluated to determine their prognostic significance in CRC.
Research methods
The authors identified the expression of B7-H3 and B3GALT4 in 223 CRC patient samples by immunohistochemistry and evaluated the possible correlation between B7-H3 and B3GALT4 and clinical outcomes. The mRNA and protein expression were also identified to establish the regulatory relationship of B7-H3 with B3GALT4 in vitro.
Research results
A significant positive correlation between B7-H3 and B3GALT4 was observed in CRC specimens. High expression of B7-H3 was identified as a significant independent predictor of poor overall survival (OS). High expression of B3GALT4 was also recognized as an independent predictor of inferior OS. In CRC cell lines with the stable expression of high B7-H3, the mRNA and protein expressions of B3GALT4 were significantly upregulated. The expression of B3GALT4 was significantly reduced when expression of B7-H3 was knocked down. 
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